content_image/31910.jpg content_image/31899.jpg content_image/31901.jpg content_image/31900.jpg content_image/31902.jpg
<img src='content_image/31910.jpg'>

<img src='content_image/31899.jpg'>

<img src='content_image/31901.jpg'>

* Growth rate in local currency is a non-GAAP financial measure. 

** Growth rate is based on 2002 and 2001 adjusted pro forma earnings per share of $1.88 and $1.48, respectively. 

*** Growth rate for 2003 is based on 2002 adjusted pro forma earnings per share of $1.88. 

(a) The adjusted amounts in 2003 exclude the after-tax effects of the following: 1) $179.2 million charge for in-process research and development related to the purchase of Oculex Pharmaceuticals, Inc., 2) $278.8 million charge for in-process research and development relat- ed to the purchase of Bardeen Sciences Company, LLC, 3) $0.4 million reversal of restructur- ing charge and asset write-offs, net related to the 2002 spin-off of the Company’s ophthalmic surgical and contact lens care businesses, 4) $0.3 million unrealized loss on derivative instru- ments, and 5) $0.9 million charge for the early extinguishment of convertible debt. 

The adjusted amounts in 2002 exclude the after-tax effects of the following: 1) $118.7 million in litigation settlement costs, 2) net costs of $100.3 million associated with the 2002 spin-off of the Company’s ophthalmic surgical and contact lens care businesses to Advanced Medical Optics 

<img src='content_image/31900.jpg'>

<img src='content_image/31902.jpg'>

which consist of restructuring charge and asset write-offs of $63.5 million, duplicate operating expenses of $42.5 million and gain of $5.7 million on sale of a facility, 3) $30.2 million loss on the other than temporary impairment of equity investments, 4) $1.7 million unrealized loss on derivative instruments, 5) net gain of $1.0 million from partnering agreements, and 6) $11.7 million charge for the early extinguishment of convertible debt. 

The adjusted amounts in 2001 exclude the $40.0 million charge for in-process research and development related to the purchase of Allergan Specialty Therapeutics, Inc. and the after-tax effects of the following: 1) $6.2 million restructuring charge and asset write-off reversal consisting of $1.7 million restructuring charge reversal and a $4.5 million gain on sale of a facility reducing the write-offs recorded in 1998, 2) income of $1.5 million from a partnering 

